CELL INTELLIGENCE · 肿瘤细胞治疗研究

多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸

Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.

四重暴露/难治性多发性骨髓瘤：既往接受过抗 CD38、IMiDs、蛋白酶体抑制剂与 BCMA 靶向治疗的患者

Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies.

多发性骨髓瘤感染风险增加的免疫生物标志物

Immune biomarkers of increased infection risk in multiple myeloma.

探索 BCMA/GPRC5D 后的治疗格局：塞利尼索、硼替佐米与地塞米松在五重难治性多发性骨髓瘤序贯免疫治疗失败后的疗效——多中心分析

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refrac

ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳：一项法国真实世界研究

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

靶向 CD19 CAR-T 细胞治疗的非 ICANS 神经毒性与运动及神经认知治疗中出现的不良事件：一例病例报告

Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case

双特异性抗体在多发性骨髓瘤中的演进

The evolution of bispecific antibodies in multiple myeloma.

肾脏病学趋势：从虚无主义到抗体介导排斥反应的靶向治疗

Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.

鉴定 CD320、SLC44A1 和 TNFRSF13B 作为多发性骨髓瘤 CAR-T 细胞治疗的潜在新靶点

Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma.

CD320、SLC44A1 和 TNFRSF13B 是多发性骨髓瘤中 CAR-T 细胞疗法有前景且具临床相关性的靶点。

SOHO 最新进展与后续问题 | 骨髓瘤早期复发的治疗：非 CAR-T 细胞

SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell.